Abstract
Background: Approximately 50% of patients with colorectal cancer at some stage of their disease develop liver metastases. Surgical resection remains the only treatment that will ensure long-term survival in 25% to 40% of patients. As a first-line treatment of metastatic colorectal cancer are recommended combination of fluorouracil with bevacizumab. Chemotherapy and bevacizumab with neoadjuvant intent enables a liver resection. In our group of 101 patients with colorectal cancer have a primary metastatic liver disease with administration of chemotherapy (FOLFOX, FOLFIRI, XELOX) and bevacizumab followed by liver resection in 29 patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.